US FDA In No Hurry To Withdraw Amgen’s Lumakras Despite Negative Adcomm Vote On Confirmatory Trial Results

 
• By Sue Sutter
Balance beam
In a meeting filled with "statistical gymnastics," FDA's advisory committee said PFS results from CodeBreaK 200 could not be relied upon. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers